StockNews.AI
DRMA
StockNews.AI
208 days

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

1. Dermata closed a private placement for 2 million shares at $1.27 each. 2. Gross proceeds from the offering amounted to approximately $2.55 million.

2m saved
Insight
Article

FAQ

Why Neutral?

The private placement raises funds but dilutes existing shares. Past similar offerings often led to temporary price stabilization.

How important is it?

The private placement is significant for immediate liquidity but has mixed outcomes for stock performance.

Why Short Term?

Initial dilution effects observed, but potential long-term growth could offset. Similar instances in biotech often show recovery post-offering.

Related Companies

DRMAW
SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrant priced at-the-market under the rules of the Nasdaq Stock Market. The gross proceeds from the offering were approximately $2.55 million, prior to deducting placement agent's fees and other offering expenses payable by the Company.

Related News